EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer

Lahari Ramagiri, Kai C C Johnson, Margaret E Gatti-Mays, Ashley P Davenport

Case Reports in Oncology · 22.09.2026

DOI: 10.1159/cro/abzag014 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 22.09.2026. Verfasst von Lahari Ramagiri und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, The Ohio State University, Columbus, OH, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Trastuzumab and pertuzumab, in combination with chemotherapy, are first-line anti- human epidermal growth factor 2 (HER2) therapies in the treatment of HER2-positive metastatic breast cancer. Although these therapies have been shown to improve the overall survival of patients, they can also be associated with adverse events; ocular toxicities have not been well-documented. Case Presentation: This report outlines the case of a patient with a spectrum of new-onset transient ocular symptoms on pertuzumab-trastuzumab combination therapy that improved with cessation of the drug and recurred with trastuzumab monotherapy rechallenge. She developed ocular symptoms 2 years into her treatment course. Her principal ophthalmologic diagnosis was dry eye syndrome of bilateral lacrimal glands and keratoconjunctivitis sicca. Ultimately, she opted for close observation in lieu of continuing therapy. Her staging scans show no evidence of disease, and she denies eye-related symptom recurrence.

Conclusion

Given the limited knowledge regarding the long-term ocular adverse events of HER2-targeted therapies, medical oncologists should routinely ask patients about new-onset or worsening ophthalmic symptoms.

Schlagwörter

Stichwörter der Autor:innen

Case reportPertuzumabToxicityTrastuzumab

Autor:innen und Institutionen

  • College of Medicine, The Ohio State University, Columbus, OH, USA.
  • Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Zitieren

APA

Ramagiri, L., Johnson, K. C. C., Gatti-Mays, M. E., & Davenport, A. P. (2026). Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer. Case Reports in Oncology. https://doi.org/10.1159/cro/abzag014

Vancouver

Ramagiri L, Johnson KCC, Gatti-Mays ME, Davenport AP. Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer. Case Reports in Oncology. 2026. doi:10.1159/cro/abzag014

BibTeX
@article{Ramagiri2026,
  author = {Ramagiri, Lahari and Johnson, Kai C C and Gatti-Mays, Margaret E and Davenport, Ashley P},
  title = {Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer},
  journal = {Case Reports in Oncology},
  year = {2026},
  doi = {10.1159/cro/abzag014}
}
Kostenlos starten →